CSTL

CASTLE BIOSCIENCES INC

Nasdaq · Services-Medical Laboratories · Inc. DE · CIK 0001447362
$21.01 -2.73% $637.2M
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)3 New Institutional Positions
Vol
Market Cap$637.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$138.6M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 11S
Insider Net $-$1.7M
SEC Reports8
Press Releases2
Exchange Nasdaq·Sector Services-Medical Laboratories·Inc. DE·CIK 0001447362·Prev Close $21.60

Recent Activity

Jun 1, 2026 SEC
CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences common stock, with an e
144 — Impact 4/10
Jun 1, 2026 Insider
MAETZOLD DEREK J sold 204 shares
Pres. & Chief Exec. Officer @ $2.39 ($487.56)
Jun 1, 2026 Insider
MAETZOLD DEREK J sold 6,214 shares
Pres. & Chief Exec. Officer @ $20.86 ($129.6K)
Jun 1, 2026 Insider
MAETZOLD DEREK J sold 204 shares
Pres. & Chief Exec. Officer @ $0.00 ($0.00)
May 7, 2026 SEC
CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10b5-1 trading plan ad
144 — Impact 3/10
May 6, 2026 earnings_calendar
CSTL Q1 2026 Earnings Scheduled — 2026-05-06
Apr 8, 2026 SEC
Castle Biosciences Inc. (CSTL) has filed a definitive proxy statement for its upcoming annual shareholder meeting. The f
DEFA14A — Impact 3/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
84,066 shares ($3.3M)

Price Targets

$44.00 +109.4% upside Strong Buy
Current $21.01 Low $35.00 Median $44.00 High $52.00 8 analysts
$35.00 $52.00

Analyst Ratings

Strong Buy93% buy · 14 analysts
7Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 13, 2026 BTIG MAINTAIN Buy → Buy
May 7, 2026 Baird MAINTAIN Outperform → Outperform
Apr 20, 2026 Canaccord Genuity MAINTAIN Buy → Buy
Feb 27, 2026 Baird MAINTAIN Outperform → Outperform
Jan 26, 2026 Guggenheim MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.40 ▼ -29.8% $-0.53 — $-0.30 -365% YoY 8
Next Q $-0.29 ▼ -52.9% $-0.41 — $-0.14 -1363% YoY 8
Current FY $-1.39 ▼ -18.1% $-1.74 — $-0.84 -67% YoY 8
Next FY $-0.93 ▼ -70.3% $-1.67 — $-0.37 33% YoY 8

Latest Reports

NEUTRAL 144 4/10
CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences common stock, with an e
Jun 1, 2026
NEUTRAL 144 3/10
CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10b5-1 trading plan ad
May 7, 2026
BULLISH Press 7/10
Castle Biosciences announced publication of data from a large prospective study showing its DecisionDx-Melanoma i31-SLNB
Mar 13, 2026

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$85.6M—
RENAISSANCE TECHNOLOGIES LLC$19.2MADD
BANK OF AMERICA CORP$10.2M—
CHARLES SCHWAB INVESTMENT MANAGEMENT$9.4MNEW
MORGAN STANLEY$7.9MADD

Recent Insider Trades

DateInsiderTypeValue
Jun 1, 2026MAETZOLD DEREKM$487.56
Jun 1, 2026MAETZOLD DEREKSELL$129.6K
Jun 1, 2026MAETZOLD DEREKM$0.00
May 28, 2026Cole GA$0.00
May 28, 2026BRADBURY DANIELA$0.00
8 institutional holders with $138.6M total value (3,562,624 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC2,199,829$85.6M61.7%—
2RENAISSANCE TECHNOLOGIES LLC493,100$19.2M13.8%ADD +39.9%
3BANK OF AMERICA CORP /DE/263,019$10.2M7.4%—
4CHARLES SCHWAB INVESTMENT MANAGEMENT INC242,535$9.4M6.8%NEW
5MORGAN STANLEY203,577$7.9M5.7%ADD +60.9%
6TWO SIGMA INVESTMENTS, LP84,066$3.3M2.4%DOUBLED +227.1%
7FMR LLC42,286$1.6M1.2%ADD +48.2%
8WELLS FARGO & COMPANY/MN34,212$1.3M1.0%ADD +42.7%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
TWO SIGMA INVESTMENTS, LPDOUBLED25,70084,066+227.1%$3.3M2025-Q4
FMR LLCADD28,54242,286+48.2%$1.6M2025-Q4
WELLS FARGO & COMPANY/MNADD23,97934,212+42.7%$1.3M2025-Q4
MORGAN STANLEYADD167,588269,631+60.9%$6.1M2025-Q3
UBS Group AGDOUBLED48,759363,848+646.2%$7.4M2025-Q2
TWO SIGMA INVESTMENTS, LPNEAR_EXIT139,78528,241-79.8%$576.7K2025-Q2
FMR LLCDOUBLED1,15624,000+1976.1%$490.1K2025-Q2
CITADEL ADVISORS LLCTRIM884,012272,882-69.1%$5.5M2025-Q1
MORGAN STANLEYTRIM306,677211,793-30.9%$4.2M2025-Q1
TWO SIGMA INVESTMENTS, LPNEW—139,785—$2.8M2025-Q1
UBS Group AGNEAR_EXIT839,00048,759-94.2%$976.2K2025-Q1
CITADEL ADVISORS LLCADD694,916884,012+27.2%$23.6M2024-Q4
UBS Group AGDOUBLED80,534839,000+941.8%$22.4M2024-Q4
RENAISSANCE TECHNOLOGIES LLCADD489,562685,000+39.9%$18.3M2024-Q4
WELLS FARGO & COMPANY/MNADD11,91515,375+29.0%$409.7K2024-Q4
MORGAN STANLEYADD249,380396,919+59.2%$11.3M2024-Q3
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW—274,761—$7.8M2024-Q3
9 unique insiders with 11 transactions. Net insider value: -$1.7M ($0.00 bought, $1.7M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 1, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM204$2.39$487.56
Jun 1, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL6,214$20.86$129.6K
Jun 1, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM204$0.00$0.00
May 28, 2026Cole G BradleyDirectorA11,766$0.00$0.00
May 28, 2026BRADBURY DANIELDirectorA11,766$0.00$0.00
May 28, 2026Caple KimDirectorA11,766$0.00$0.00
May 28, 2026Cotton RodneyDirectorA11,766$0.00$0.00
May 28, 2026Olson TiffanyDirectorA11,766$0.00$0.00
May 28, 2026Goldberg EllenDirectorA11,766$0.00$0.00
May 28, 2026Harrison MilesDirectorA11,766$0.00$0.00
May 22, 2026Caple KimDirectorM13,667$0.00$0.00
May 22, 2026Caple KimDirectorM13,667$0.00$0.00
May 22, 2026Cotton RodneyDirectorM13,667$0.00$0.00
May 22, 2026Cotton RodneyDirectorM13,667$0.00$0.00
May 22, 2026Goldberg EllenDirectorM13,667$0.00$0.00
May 22, 2026Goldberg EllenDirectorM13,667$0.00$0.00
May 22, 2026Olson TiffanyDirectorM13,667$0.00$0.00
May 22, 2026Olson TiffanyDirectorM13,667$0.00$0.00
May 22, 2026BRADBURY DANIELDirectorM13,667$0.00$0.00
May 22, 2026Harrison MilesDirectorM13,667$0.00$0.00
May 22, 2026BRADBURY DANIELDirectorM13,667$0.00$0.00
May 22, 2026Harrison MilesDirectorM13,667$0.00$0.00
May 22, 2026Cole G BradleyDirectorM13,667$0.00$0.00
May 22, 2026Cole G BradleyDirectorM13,667$0.00$0.00
May 21, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM420$2.39$1.0K
May 21, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL420$20.20$8.5K
May 21, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM420$0.00$0.00
May 21, 2026Juvenal Tobin WChief Commercial OfficerM11,210$0.00$0.00
May 21, 2026Juvenal Tobin WChief Commercial OfficerM11,210$3.38$37.9K
May 20, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM130$2.39$310.70
May 20, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL130$20.00$2.6K
May 20, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM130$0.00$0.00
May 7, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM6,214$2.39$14.9K
May 7, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL5,308$22.08$117.2K
May 7, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM6,214$0.00$0.00
Apr 21, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL550$25.10$13.8K
Apr 21, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM550$2.39$1.3K
Apr 21, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM550$0.00$0.00
Apr 6, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM6,214$0.00$0.00
Apr 6, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL6,214$25.03$155.5K
Apr 6, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM6,214$2.39$14.9K
Mar 26, 2026Cotton RodneyDirectorM5,329$0.00$0.00
Mar 26, 2026Cotton RodneyDirectorM5,329$0.00$0.00
Mar 26, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM550$2.39$1.3K
Mar 26, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL550$25.55$14.1K
Mar 26, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerM550$0.00$0.00
Mar 18, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL650$25.39$16.5K
Mar 17, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL18,650$25.93$483.6K
Mar 16, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL17,449$25.96$453.0K
Mar 13, 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSELL13,204$25.45$336.0K
8 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 4 neutral. Avg impact: 4.8/10.
NEUTRAL 144 4/10
CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences com
Jun 1, 2026
NEUTRAL 144 3/10
CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10
May 7, 2026
NEUTRAL DEFA14A 3/10
Castle Biosciences Inc. (CSTL) has filed a definitive proxy statement for its upcoming annual shareh
Apr 8, 2026
BEARISH CLUSTER 6/10
Castle Biosciences CEO Derek Maetzold sold 49,953 shares in the past week through open-market transa
Mar 19, 2026
BEARISH CLUSTER 7/10
CEO Derek Maetzold and Chief Commercial Officer Juvenal Tobin sold a combined $2.4M in open-market t
Mar 17, 2026
BEARISH CLUSTER 7/10
Multiple C-suite executives at Castle Biosciences sold shares in a concentrated 7-day window, includ
Mar 16, 2026
BEARISH CLUSTER 5/10
Castle Biosciences CEO Derek Maetzold sold a total of 40,489 shares in the past week, generating app
Mar 13, 2026
NEUTRAL CLUSTER 3/10
Castle Biosciences insiders executed a cluster of transactions over the past week, primarily involvi
Mar 9, 2026
BULLISH 7/10
Castle Biosciences announced publication of data from a large prospective study showing its Decision
Mar 13, 2026
BULLISH 7/10
Castle Biosciences announced new prospective, multicenter study data showing that its DecisionDx-Mel
Mar 9, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 7 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$44.00 mean target +109.4% upside Strong Buy (1.00)
$35.00 Low $52.00 High
MetricValue
Current Price$21.01
Target Low$35.00
Target Mean$44.00
Target Median$44.00
Target High$52.00
# Analysts8
RecommendationStrong Buy (1.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.40 $-0.53 $-0.30 -365.0% -29.8% 2↑ 6↓ $0.1B 0.1% 8
Next Q
2026-09-30
 $-0.29 $-0.41 $-0.14 -1362.5% -52.9% 2↑ 6↓ $0.1B 8.8% 8
Current FY
2026-12-31
 $-1.39 $-1.74 $-0.84 -66.9% -18.1% 3↑ 5↓ $0.4B 2.4% 8
Next FY
2027-12-31
 $-0.93 $-1.67 $-0.37 32.8% -70.3% 2↑ 6↓ $0.4B 11.5% 8

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.398
7d ago$-0.396-0.001
30d ago$-0.306-0.091
60d ago$-0.306-0.091
90d ago$-0.319-0.079
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 13, 2026 BTIG MAINTAIN Buy Buy
May 7, 2026 Baird MAINTAIN Outperform Outperform
Apr 20, 2026 Canaccord Genuity MAINTAIN Buy Buy
Feb 27, 2026 Baird MAINTAIN Outperform Outperform
Jan 26, 2026 Guggenheim MAINTAIN Buy Buy
Jan 12, 2026 Lake Street MAINTAIN Buy Buy
Jan 5, 2026 Guggenheim MAINTAIN Buy Buy
Dec 22, 2025 Canaccord Genuity MAINTAIN Buy Buy
Dec 12, 2025 BTIG MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20267610093%
May 1, 20267610093%
Apr 1, 20267610093%
Mar 1, 20267610093%
Feb 1, 20266610092%
Jan 1, 20267610093%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 6, 2026
earnings_calendar
CSTL Q1 2026 Earnings Scheduled — 2026-05-06
Mar 13, 2026
fda
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma’s integrated SLNB test result.
Mar 9, 2026
fda
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB
Mar 4, 2026
other
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
Mar 3, 2026
other
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time.
Feb 26, 2026
earnings_calendar
CSTL Q4 2025 Earnings After Market Close — 2026-02-26
Feb 2, 2026
short_interest
FTD: CSTL — 19,689 shares ($0.8M) failed to deliver
Settlement: 20260202, Price: $39.39, FTD Value: $775,549.71, CASTLE BIOSCIENCES INC COM